P-METHOXYACETANILIDE
NASH - Nonalcoholic Steatohepatitis
Meridian Bioscience, Inc.Small moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
24 Active assets in the NASH - Nonalcoholic Steatohepatitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Empagliflozin Badr University | Phase 4 | BBB |
Lipitor Badr University | Phase 4 | BB |
Sitagliptin NeuroBo Pharmaceuticals Inc. | Phase 4 | BB |
Aldafermin NGM Biopharmaceuticals, Inc | Phase 2 | BB |
DULAGLUTIDE Central Hospital, Nancy, France | Phase 4 | BB |
View all 50 →
Same molecule, other indications
P-METHOXYACETANILIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →